Abstract
Overproduction of reactive oxygen species (ROS) under pathophysiologic conditions is part of the disease process. These ROS are released from different sources, and in particular from mitochondria. Although the molecular mechanisms responsible for mitochondria- mediated disease processes are unclear, oxidative stress seems to play an important role. ROS are essential to cell function, but adequate levels of antioxidant defenses are required in order to avoid the harmful effects that excessive ROS production can produce. Mitochondrial oxidative stress damage and dysfunction contribute to a number of cell pathologies that manifest themselves through a range of conditions. The antioxidants available until now have not proved to be particularly effective against many of these disorders. It is possible that these antioxidants do not reach the sites of free radical generation, especially when mitochondria are the primary source of ROS. Recent developments in mitochondria-_targeted antioxidants have moved closer to providing protection against mitochondrial oxidative damage. The SS (Szeto-Schiller) peptide antioxidants represent a novel approach that employs the _targeted delivery of antioxidants to the inner mitochondrial membrane. These SS peptides scavenge hydrogen peroxide and peroxynitrite and inhibit lipid peroxidation. By reducing mitochondrial ROS, they inhibit mitochondrial permeability transition and cytochrome c release, thus preventing oxidant-induced cell death. Preclinical studies support the use of these peptides for ischemia-reperfusion injury and neurodegenerative disorders. Although peptides have often been considered to be poor drug candidates, the few that have been studied are promising agents for the treatment of diseases.
Keywords: Antioxidant peptides, mitochondria, oxidative stress
Current Pharmaceutical Design
Title: Mitochondria-_targeted Antioxidant Peptides
Volume: 16 Issue: 28
Author(s): Milagros Rocha, Antonio Hernandez-Mijares, Katherinne Garcia-Malpartida, Celia Banuls, Lorena Bellod and Victor M. Victor
Affiliation:
Keywords: Antioxidant peptides, mitochondria, oxidative stress
Abstract: Overproduction of reactive oxygen species (ROS) under pathophysiologic conditions is part of the disease process. These ROS are released from different sources, and in particular from mitochondria. Although the molecular mechanisms responsible for mitochondria- mediated disease processes are unclear, oxidative stress seems to play an important role. ROS are essential to cell function, but adequate levels of antioxidant defenses are required in order to avoid the harmful effects that excessive ROS production can produce. Mitochondrial oxidative stress damage and dysfunction contribute to a number of cell pathologies that manifest themselves through a range of conditions. The antioxidants available until now have not proved to be particularly effective against many of these disorders. It is possible that these antioxidants do not reach the sites of free radical generation, especially when mitochondria are the primary source of ROS. Recent developments in mitochondria-_targeted antioxidants have moved closer to providing protection against mitochondrial oxidative damage. The SS (Szeto-Schiller) peptide antioxidants represent a novel approach that employs the _targeted delivery of antioxidants to the inner mitochondrial membrane. These SS peptides scavenge hydrogen peroxide and peroxynitrite and inhibit lipid peroxidation. By reducing mitochondrial ROS, they inhibit mitochondrial permeability transition and cytochrome c release, thus preventing oxidant-induced cell death. Preclinical studies support the use of these peptides for ischemia-reperfusion injury and neurodegenerative disorders. Although peptides have often been considered to be poor drug candidates, the few that have been studied are promising agents for the treatment of diseases.
Export Options
About this article
Cite this article as:
Rocha Milagros, Hernandez-Mijares Antonio, Garcia-Malpartida Katherinne, Banuls Celia, Bellod Lorena and M. Victor Victor, Mitochondria-_targeted Antioxidant Peptides, Current Pharmaceutical Design 2010; 16 (28) . https://dx.doi.org/10.2174/138161210793292519
DOI https://dx.doi.org/10.2174/138161210793292519 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employed in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, and prediction, to monitoring of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Urokinase Receptor System, A Key Regulator at the Intersection between Inflammation, Immunity, and Coagulation
Current Pharmaceutical Design Halogenated Derivatives of Aromatic Amino Acids Exhibit Balanced Antiglutamatergic Actions: Potential Applications for the Treatment of Neurological and Neuropsychiatric Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Involvement of L-Carnitine in Cellular Metabolism: Beyond Acyl-CoA Transport
Mini-Reviews in Medicinal Chemistry Protein Kinase C-Related Kinase (PKN/PRK). Potential Key-Role for PKN1 in Protection of Hypoxic Neurons
Current Neuropharmacology Pulmonary Arterial Hypertension: Need to Treat
Inflammation & Allergy - Drug _targets (Discontinued) Chitosan-coated C-phycocyanin Liposome for Extending the Neuroprotective Time Window Against Ischemic Brain Stroke
Current Pharmaceutical Design The Bax Inhibitor-1 (BI-1) Family in Apoptosis and Tumorigenesis
Current Molecular Medicine Mesenchymal Stem Cell-Mediated Immuno-Modulatory and Anti- Inflammatory Mechanisms in Immune and Allergic Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Genetic Polymorphisms of Type-1 and Type-2 Inflammatory Cytokines in Ischaemic Stroke
Vascular Disease Prevention (Discontinued) Mesenchymal Stem Cells for Ischemic Stroke: Progress and Possibilities
Current Medicinal Chemistry Nitric Oxide and Pancreatic Cancer Pathogenesis, Prevention, and Treatment
Current Pharmaceutical Design Emerging Role for Antioxidant Therapy in Protection Against Diabetic Cardiac Complications: Experimental and Clinical Evidence for Utilization of Classic and New Antioxidants
Current Cardiology Reviews Oxidative Stress and Pathophysiology of Ischemic Stroke: Novel Therapeutic Opportunities
CNS & Neurological Disorders - Drug _targets Dynamics of Toll-like Receptors Signaling in Skeletal Muscle Atrophy
Current Medicinal Chemistry Mesenchymal Stem Cells in Renal Ischemia-Reperfusion Injury: Biological and Therapeutic Perspectives
Current Stem Cell Research & Therapy Lipoxins, The Novel Mediators of Gastroprotection and Gastric Adaptation to Ulcerogenic action of Aspirin
Current Pharmaceutical Design Do RAS Inhibitors Protect the Brain from Cerebral Ischemic Injury?
Current Hypertension Reviews CXCL8 as a Potential Therapeutic _target for HIV-Associated Neurocognitive Disorders
Current Drug _targets _targeting STAT1 in Both Cancer and Insulin Resistance Diseases
Current Protein & Peptide Science Therapeutic _targeting of Toll-Like Receptors in Gastrointestinal Inflammation
Current Pharmaceutical Design